ReviewDiscover oncology2025
The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain metastases (BMs) present a significant therapeutic challenge due to limited blood-brain barrier permeability, which restricts the efficacy of systemic treatments. To address this, we systematically evaluated the effectiveness and safety of encorafenib plus binimetinib in patients with BMs.
methodsWe conducted a systematic literature search from inception to January 2025 to assess the intracranial efficacy of encorafenib in combination with binimetinib. Studies reporting related outcomes were included.
resultsFour studies, encompassing 1,789 patients with 472 BMs, were included. The pooled intracranial overall response rate (ORR) was approximately 48% with substantial variability across studies. Additionally, about 29% of patients achieved stable disease (SD). Meta-regression suggested that sex, performance status, number of brain lesions, and prior treatments may influence treatment response.
conclusionEncorafenib plus binimetinib has demonstrated promising outcomes in the setting of BMs. Given the limitations of the available data, further prospective and controlled studies are required to validate our findings and identify the optimal patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.